Studies describe elevated D-dimers and fibrin degradation products (FDP), mild thrombocytopaenia, and prolonged prothrombin time [2] with the occurrence of disseminated intravascular coagulation (DIC) [3], higher rates of venous thromboembolism (VTE), and cerebrovascular accidents in critically ill COVID-19 patients [4] as well as central venous line and extracorporeal circuit thrombosis [5]. The gene discussed is F2; the disease is venous thromboembolism.